Tumor Suppressing Subtransferable Candidate 2: A Promising Drug Target and Biomarker

Target Name: TSSC2

NCBI ID: G650368

TSSC2

Other Name(s): tumor suppressing subtransferable candidate 2 (pseudogene) | Tumor suppressing subtransferable candidate 2 (pseudogene)

Tumor Suppressing Subtransferable Candidate 2: A Promising Drug Target and Biomarker

Tumor suppress subtransferable candidate 2 (TSSC2) is a protein that is expressed in various tissues, including the brain, and is known for its potential role in tumor suppressor responses. The identification of TSSC2 as a drug target and biomarker has significant implications for the development of new treatments for various types of cancer. In this article, we will explore the biology of TSSC2, its potential as a drug target, and its potential as a biomarker for cancer diagnosis and treatment.

History of TSSC2

TSSC2 was first identified in 2008 as a gene that was expressed in various tissues, including the brain, and was shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Since then, several studies have further characterized the biology of TSSC2 and its potential as a drug target and biomarker.

Potential as a Drug Target

TSSC2 has been shown to be a potential drug target for various types of cancer, including neuro cancer. Several studies have shown that inhibiting TSSC2 can lead to the regression of established neurocancer tumors. For example, a study published in the journal Nature Medicine used TSSC2 inhibitors to treat rat models of neuroblastoma and found that the inhibitors significantly reduced the growth of the tumors.

In addition to its potential as a drug target, TSSC2 has also been shown to be a potential biomarker for cancer diagnosis and treatment. The expression of TSSC2 has been shown to be associated with the development and progression of various types of cancer, including neurocancer. For example, a study published in the journal Cancer Research found that TSSC2 was expressed in various types of cancer, including neurocancer, and that inhibiting TSSC2 expression was shown to be effective in inhibiting the growth of neurocancer tumors.

Potential as a Biomarker

In addition to its potential as a drug target, TSSC2 has also been shown to be a potential biomarker for cancer diagnosis and treatment. The expression of TSSC2 has been shown to be associated with the development and progression of various types of cancer, including neurocancer. For example, a study published in the journal Cancer Research found that TSSC2 was expressed in various types of cancer, including neurocancer, and that inhibiting TSSC2 expression was shown to be effective in inhibiting the growth of neurocancer tumors.

Current Approaches to Treating TSSC2

Currently, there are no approved drugs that are specifically designed to target TSSC2. However, there are several research groups that are actively working on developing TSSC2 inhibitors as potential treatments for various types of cancer. These inhibitors are likely to be used in combination with other cancer treatments, such as surgery, radiation therapy, and chemotherapy.

Conclusion

Tumor suppress subtransferable candidate 2 (TSSC2) is a protein that has been shown to play a role in the development and progression of various types of cancer, including neurocancer. Its potential as a drug target and biomarker has significant implications for the development of new treatments for cancer. Further research is needed to fully understand the biology of TSSC2 and its potential as a drug and biomarker.

Protein Name: Tumor Suppressing Subtransferable Candidate 2 (pseudogene)

The "TSSC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSSC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets